Durvalumab after chemo-radiotherapy in stage III non-small cell lung cancer

Lung cancer is the most common cause of death worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer and a third of NSCLC patients present with unresectable locally advanced disease (1).